Literature DB >> 25994050

Histone deacetylase inhibitors: a review on class-I specific inhibition.

Jagannath Behera, Venkatesan Jayaprakash, Barij Nayan Sinha1.   

Abstract

Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25994050     DOI： 10.2174/1389557515666150521162237

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  6 in total

1.  Human Trophoblast Differentiation Is Associated With Profound Gene Regulatory and Epigenetic Changes.

Authors:  Youn-Tae Kwak; Sribalasubashini Muralimanoharan; Aishwarya A Gogate; Carole R Mendelson
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

2.  Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.

Authors:  Marguerite S Buzza; Tierra A Johnson; Gregory D Conway; Erik W Martin; Subhradip Mukhopadhyay; Terez Shea-Donohue; Toni M Antalis
Journal:  J Biol Chem       Date:  2017-05-10       Impact factor: 5.157

3.  CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.

Authors:  M Sauer; M Schuldner; N Hoffmann; A Cetintas; K S Reiners; O Shatnyeva; M Hallek; H P Hansen; S Gasser; E P von Strandmann
Journal:  Oncogene       Date:  2016-08-01       Impact factor: 9.867

4.  Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.

Authors:  Xiaodi Qiu; Xianfang Rong; Jin Yang; Yi Lu
Journal:  BMC Ophthalmol       Date:  2019-02-04       Impact factor: 2.209

Review 5.  Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success.

Authors:  John A Halsall; Bryan M Turner
Journal:  Bioessays       Date:  2016-09-22       Impact factor: 4.345

6.  Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.

Authors:  Xu-Wen Guan; Hua-Qing Wang; Wei-Wei Ban; Zhi Chang; Hai-Zhu Chen; Li Jia; Feng-Ting Liu
Journal:  Cell Death Dis       Date:  2020-01-06       Impact factor: 8.469
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.